SCO Update on Ovarian Suppression in HR-Positive Breast Cancer

Options
cp418
cp418 Member Posts: 7,079
edited February 2016 in Clinical Trials, Research News, Podcasts, and Study Results

http://www.practiceupdate.com/c/35661/2/1/?elsca1=...


ASCO Update on Ovarian Suppression in HR-Positive Breast Cancer

· Share on FacebookShare on Twitter

Comments

  • 123JustMe
    123JustMe Member Posts: 385
    edited May 2016
    TAKE-HOME MESSAGE

    The new ASCO guidelines suggest that higher-risk patients with ER-positive breast cancer should receive ovarian suppression in addition to adjuvant endocrine therapy, but that lower-risk patients should not.

    Women with stage II or III breast cancers who would normally receive adjuvant chemotherapy should now receive ovarian suppression with endocrine therapy. In addition, ovarian suppression with endocrine therapy should be offered to women with stage I or II breast cancers at higher risk of recurrence and who are receiving chemotherapy but not to women with stage I breast cancers not warranting chemotherapy or those with node-negative cancers measuring 1 cm or less. Ovarian suppression may be given with either tamoxifen or an aromatase inhibitor.

    Abstract
    · Share on FacebookShare on Twitter
  • BarredOwl
    BarredOwl Member Posts: 2,433
    edited February 2016

    Thanks cp418. Is this the document of interest or does the practice update include something else?

    February, 2016: "Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression"

    http://jco.ascopubs.org/content/early/2016/02/11/J...

    BarredOwl


    · Share on FacebookShare on Twitter
  • cp418
    cp418 Member Posts: 7,079
    edited February 2016

    All links mentioned appear to be for the same ASCO guidelines update.

    · Share on FacebookShare on Twitter

Categories